Sema4 to acquire GeneDx from OPKO Health

Sema4 announced a definitive agreement to acquire GeneDx, a subsidiary of OPKO Health, strengthening its genomic and clinical data platform. The deal is projected to deliver $350 million in pro forma 2022 revenue, with a $200 million private placement from investors including Pfizer.

“Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) today announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc.”nasdaq.com

• 1 source
• nasdaq.comSema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform | NasdaqJan 18, 2022

Summarized from public sources; check the original articles before acting on it.